ReachMD publik
[search 0]
Lebih
Unduh Aplikasinya!
show episodes
 
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
  continue reading
 
Loading …
show series
 
CME credits: 0.25 Valid until: 07-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-adherence-and-persistence-with-durable-anti-vegf-therapies-for-namd/18068/ This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neov…
  continue reading
 
CME credits: 0.50 Valid until: 30-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/cd20-x-cd3-bispecificsredefining-treatment-for-patients-with-rr-dlbcllbcl-in-the-community-setting/17877/ In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent …
  continue reading
 
CME credits: 0.25 Valid until: 30-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/evolving-our-view-of-the-coagulation-cascade-and-stroke-management/24144/ How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of…
  continue reading
 
CME credits: 0.25 Valid until: 29-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consensus-recommendations-for-use-of-p16ki67-dual-staining-cytology-in-the-management-of-individuals-testing-positive-for-hpv/14675/ More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the pote…
  continue reading
 
CME credits: 0.25 Valid until: 22-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/strategic-excellence-mastering-the-expanding-attr-cm-therapeutic-landscape-in-pharmacy-practice/18124/ Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM managem…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-following-scrt-vs-rt-only-in-stage-iii-nsclc/24388/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, a…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/immunotherapy-approaches-in-unresectable-stage-iii-nsclc-whats-on-the-horizon/24390/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectabili…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-case-discussion/24392/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining re…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/chemoradiotherapy-toxicities-how-do-they-impact-starting-immunotherapy/24389/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, app…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidation-immunotherapy-after-concurrent-crt-what-do-real-world-data-show/24387/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectabili…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/differentiating-and-managing-pneumonitis-in-unresectable-stage-iii-nsclc-case-discussion/24393/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining …
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/accurate-staging-and-determining-resectability-in-nsclc/24385/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical …
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/consolidative-immunotherapy-in-unresectable-stage-iii-nsclc-with-oncogenic-drivers/24391/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resect…
  continue reading
 
CME credits: 1.00 Valid until: 15-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/resolving-practice-barriers-to-consolidative-immunotherapy-in-stage-iii-nsclc/24386/ In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectabili…
  continue reading
 
CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/initial-btk-inhibitor-based-treatment-selection-in-a-treatment-naive-symptomatic-unfit-older-patient-with-comorbidities-and-high-risk-cytogenetics/24452/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizi…
  continue reading
 
CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-changing-covalent-btk-inhibitor-treatment-in-a-patient-intolerant-to-ibrutinib-or-acalabrutinib/24454/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences betwe…
  continue reading
 
CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/selection-of-btk-inhibitor-following-frontline-chemoimmunotherapy-in-older-patients-with-comorbidities/24453/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-g…
  continue reading
 
CME credits: 0.25 Valid until: 09-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/attr-cm-management-pearls-from-recent-clinical-trials-and-tailoring-therapy/18005/ Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to t…
  continue reading
 
CME credits: 0.50 Valid until: 09-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimal-sequencing-of-adcs-in-endocrine-refractory-hrher2-metastatic-breast-cancer/18104/ The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast ca…
  continue reading
 
CME credits: 1.00 Valid until: 06-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/are-two-pathways-better-than-one-experts-discuss-the-role-of-ang2-vegfa-inhibition-in-retinal-vascular-disease/16620/ Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of re…
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic …
  continue reading
 
CME credits: 1.00 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/evolutions-in-duchenne-muscular-dystrophy-treatment-implications-for-the-present-and-future/20369/ There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitabl…
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell car…
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They d…
  continue reading
 
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic …
  continue reading
 
Loading …

Panduan Referensi Cepat